EP0086192A4 - Segmented polyurethane composition. - Google Patents

Segmented polyurethane composition.

Info

Publication number
EP0086192A4
EP0086192A4 EP19810902427 EP81902427A EP0086192A4 EP 0086192 A4 EP0086192 A4 EP 0086192A4 EP 19810902427 EP19810902427 EP 19810902427 EP 81902427 A EP81902427 A EP 81902427A EP 0086192 A4 EP0086192 A4 EP 0086192A4
Authority
EP
European Patent Office
Prior art keywords
composition
diamine
implantation
human body
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19810902427
Other languages
German (de)
French (fr)
Other versions
EP0086192A1 (en
Inventor
Edward W Merrill
Stephen S Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of EP0086192A1 publication Critical patent/EP0086192A1/en
Publication of EP0086192A4 publication Critical patent/EP0086192A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
    • C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
    • C08G18/751—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing only one cycloaliphatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/48—Polyethers
    • C08G18/4825—Polyethers containing two hydroxy groups

Definitions

  • This invention relates to new segmented polyurethane composition useful in biomedical surface applications.
  • Segmented polyurethanes have been widely studied and used in intravascular applications requiring contact with blood such as angiographic catheters.
  • Their thrombogenic potential, especially their ability to activate platelets, has usually been regarded as favorably low, but substantial variations have been reported.
  • the segmented polyurethanes depend upon separa ⁇ tion of two mutually incompatible molecular sequences for their mechanical integrity.
  • One sequence known as the "soft" segment can be a polyether. This constitutes the continuous plase and is rubbery at temperatures of use.
  • the other sequence known as the "hard” segment consists of strongly hydrogen-bonding structural units derived from diisocyanates and dia ines, which cluster in the discontinuous phase as glassy or crystalline micelles, thereby serving as effective junctions to connect the soft segment sequences.
  • the composition of the material at the surface is not usually identical to that in the interior when surface free energy is allowed to act.
  • polyether polyurethanes Prior to the present invention, polyether polyurethanes have been prepared by reacting an ⁇ , ⁇ -polyether diol such as polytetramethylene oxide, polypropylene oxide or polyethylene oxide with 2,4-tolylene diisocyanate or 4,4'-diphenylmethane diisocyanate followed by chain extension with a diamine.
  • an ⁇ , ⁇ -polyether diol such as polytetramethylene oxide, polypropylene oxide or polyethylene oxide
  • 2,4-tolylene diisocyanate or 4,4'-diphenylmethane diisocyanate 2,4-tolylene diisocyanate or 4,4'-diphenylmethane diisocyanate
  • the present invention is based upon the discovery that by forming a segmented polyurethane by end-capping an ⁇ , ⁇ dihydroxy polyalkylene oxide with 1,4-transcyclohexane diisocyanate which is then extended by a diamine or a short diol, has a very low or zero nitrogen content on the surface thereof.
  • the compositions of this invention are ex ⁇ tremely bland toward blood platelets and are useful as coat- ings for devices implanted or inserted into the human body such as intravenous catheters, heart valves or the like.
  • an ⁇ , ⁇ dihydroxy polyalkylene oxide is end capped with 1,4-transcyclohexane diisocyanate which is then extended with a diamine or a short diol in either a two-step or a three-step procedure.
  • Repre ⁇ sentative suitable polyalkylene oxides include polytetra ⁇ methylene oxide, polypropylene oxide, polyethylene oxide or
  • the polyalkylene oxide is dissolved in a suitable solvent such as a mixture of dimethyl sulfoxide and 4-methyl- 2-pentanone. To this solution is added the 1,4-transcyclo- hexane diisocyanate. Given the amount of polyether known, the amount of diisocyanate is calculated as to have a 1:2 mole ratio in a two-step synthesis, or 1:0.5 mole ratio in the first addition and 1:1 mole ratio in the second addition in a three-step synthesis. This addition is conducted in the absence of oxygen in order to avoid undesirable side reactions. Any inert atmosphere can be utilized such as argon, nitrogen or the like.
  • the addition of the diisocyan ⁇ ate reactant can be performed in one step (as in a two-step synthesis) or in multiple steps, usually two steps (as in a three-step synthesis) .
  • the resultant mixture is then heated to a temperature below 100°C, preferably between about 80 and about 90°C for a period of time usually between about 7 hours and about 10 hours.
  • the resultant mixture then is allowed to cool, usually to about room temperature and the diamine or short diol can be added to the mixture in order to effect the desired polymeric extension.
  • suitable diamines and diols include ethylene diamine, hydra- zine, ethylene glycol, butane-l,4-diol.
  • the diamine or diol be capable of reacting with residual isocyanate groups.
  • the preferred extender is ethyl- ene diamine. Given the amount of diisocyanate known, the amount of extender is calculated as to have a 2:1 mole ratio in a two-step synthesis, or a 3:1 ratio in a three-step synthesis.
  • the extension reaction can be conducted at room temperature wherein the extender is usually added dropwise in solution of a suitable solvent such as 3% solution in di ⁇ methyl sulfoxide. The resultant product then is recovered by removing the solvent.
  • the resultant product is rubbery and soluble in hexafluoroisopropanol, formic acid and m- cresol, but insoluble in N,N-dimethylformamide (DMF) .
  • DMF N,N-dimethylformamide
  • compositions of this invention when cast as films from solutions, as examined by x-ray photoelectron spectroscopy, are nearly pure poiy- ether, generally about 80% or more which provides a strong basis that phase separation of the "hard segment” is much more complete and that the hard segment (diisocyanate-diamine) is below the surface. This contrasts with the prior art segmented polyurethanes which show no more than about 60% polyether at the surface.
  • Figures 1 and 2 are plotted as the number of elec ⁇ trons divided by their kinetic energy LN(E) as a function of their binding energy in electron volts when segmented polyurethanes are examined by x-ray photoelectron spectos- copy.
  • Figure 1 shows the proportion of oxygen, nitrogen and carbon on the surface of a segmented polyurethane pre ⁇ pared from polyethylene oxide, molecular weight 15000, 2,4- tolylene diisocyanate, 4,4*-diphenylmethane diisocyanate and ethylene diamine by the three-step procedure generally set forth in Example I, but utilizing dimethylformamide as the solvent.
  • This segmented polyurethane represents one of the best nonthrombogenic segmented polyurethanes made by the prior art process. It shows strong oxygen and carbon peaks and some nitrogen peaks. In contrast, the curve of Figure 2 which utilized the segmented polyurethane produced by the three-step procedure of Example I shows no nitrogen. A comparison of the carbon to oxygen ether bonds on each of these surfaces shows the prior art fraction of carbon bonded to ether to be only about 0.6 while that of the surface pro-
  • composition of this invention can be dissolved in a suitable solvent and the resultant composition can be coated on any device inserted or implanted in the body in order to reduce thrombogenicity of the device such as a heart valve, intravenous catheter or the like.
  • the reaction is quenched with 100 ml of meth- anol.
  • DMSO, methanol and 4-methyl-2-pentanone are evaporated to leave behind a lemonly-yellow gel-like polyurethane.
  • the polyurethane is precipitated and extensively washed in dis ⁇ tilled water and dried in an oven at 60 C for a week, in vacuo.
  • the product is rubbery and soluble in hexafluoroiso- propanol (HFIP) , formic acid, and m-cresol, but insoluble in N,N-dimethylformamide (DMF) .
  • HFIP hexafluoroiso- propanol
  • DMF N,N-dimethylformamide
  • OMPI . foxide DMSO
  • 4-methyl-2-pentanone 1.66 grams of trans- 1,4-cyclohexane-diisocy.anate (CHDI) are then added into the mixture. The mixture is stirred under argon for 8 hours at 85°C. 3.32 grams of CHDI are added into the reactor and the mixture is stirred under argon for another 8 hours at 85 C. The mixture becomes lemonly-yellow and somewhat turbid. The reactor is allowed to cool to room temperature. 400 ml of DMSO are added to the cooled mixture. 0.61 grams of ethyl- enediamine is then added drop by drop to the reactor as a 3% solutionn DMSO in continuous stirring.
  • CHDI trans- 1,4-cyclohexane-diisocy.anate
  • reaction is quenched with 100 ml of methanol, DMSO, methanol and 4-methyl-2-pentanone are evaporated to leave behind a lemonly-yellow gel-like polyurethane.
  • the poly ⁇ urethane is precipitated and extensively washed in distilled water and dried in an oven at 60 C for a week, in vacuo.
  • the product is rubbery and soluble in hexafluoroisopropanol (HFIP) , formic acid and m-cresol, but insoluble in N,N-di- methyl ormamide (DMF) .
  • HFIP hexafluoroisopropanol
  • DMF N,N-di- methyl ormamide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Nonthrombogenic surfaces are formed from a polyurethane by end-capping an alpha , omega dihydroxy polyalkylene oxide with 1,4-transcyclohexane diisocyanate, which is then extended with a diamine or a short diol. Surfaces of body implants, coated with solutions of the above, are extremely bland toward blood platelets.

Description

SEGMENTED POLYURETHANE COMPOSITION
Background of the Invention
This invention relates to new segmented polyurethane composition useful in biomedical surface applications.
Segmented polyurethanes have been widely studied and used in intravascular applications requiring contact with blood such as angiographic catheters.. Their thrombogenic potential, especially their ability to activate platelets, has usually been regarded as favorably low, but substantial variations have been reported. Unlike homopolymers such as polyacrylates, in which surface and bulk compositions are identical, the segmented polyurethanes depend upon separa¬ tion of two mutually incompatible molecular sequences for their mechanical integrity. One sequence known as the "soft" segment can be a polyether. This constitutes the continuous plase and is rubbery at temperatures of use. The other sequence known as the "hard" segment consists of strongly hydrogen-bonding structural units derived from diisocyanates and dia ines, which cluster in the discontinuous phase as glassy or crystalline micelles, thereby serving as effective junctions to connect the soft segment sequences. In such a two phase material, the composition of the material at the surface is not usually identical to that in the interior when surface free energy is allowed to act.
It is known that the chemical analogs of the hard segment, for example, the copolymer of a diisocyanate and diamine, strongly cause platelet activation. The average fraction of platelets retained on such materials when whole blood is passed over them is about 0.8. For an "ideally bland" surface, the average fraction of platelets retained on such materials should be 0. To the extent that this phase
SUBSTITUTE SHEET _ O PI_ appears in blood contacting surfaces of the polyurethanes, thrombogenicity is to be expected.
Prior to the present invention, polyether polyurethanes have been prepared by reacting an α,ω-polyether diol such as polytetramethylene oxide, polypropylene oxide or polyethylene oxide with 2,4-tolylene diisocyanate or 4,4'-diphenylmethane diisocyanate followed by chain extension with a diamine. When cast as films from an appropriate polar solvent such as dimethyl fomamide, the best achievement of segmentation of the hard segment of the resultant polymer to below the sur¬ face of the film is about 60% as measured by x-ray photo- electron spectroscopy. It would be highly desirable to pro¬ vide such polymers wherein the soft segment of the polymer occupies as much of the surface as possible, in any event greater than about 60% of the surface.
Summary of the Invention
The present invention is based upon the discovery that by forming a segmented polyurethane by end-capping an α,ω dihydroxy polyalkylene oxide with 1,4-transcyclohexane diisocyanate which is then extended by a diamine or a short diol, has a very low or zero nitrogen content on the surface thereof. Thus, the compositions of this invention are ex¬ tremely bland toward blood platelets and are useful as coat- ings for devices implanted or inserted into the human body such as intravenous catheters, heart valves or the like.
Description of Specific Embodiments
In accordance with this invention, an α,ω dihydroxy polyalkylene oxide is end capped with 1,4-transcyclohexane diisocyanate which is then extended with a diamine or a short diol in either a two-step or a three-step procedure. Repre¬ sentative suitable polyalkylene oxides include polytetra¬ methylene oxide, polypropylene oxide, polyethylene oxide or
-^tJE.E > ' the like. The polyalkylene oxide is dissolved in a suitable solvent such as a mixture of dimethyl sulfoxide and 4-methyl- 2-pentanone. To this solution is added the 1,4-transcyclo- hexane diisocyanate. Given the amount of polyether known, the amount of diisocyanate is calculated as to have a 1:2 mole ratio in a two-step synthesis, or 1:0.5 mole ratio in the first addition and 1:1 mole ratio in the second addition in a three-step synthesis. This addition is conducted in the absence of oxygen in order to avoid undesirable side reactions. Any inert atmosphere can be utilized such as argon, nitrogen or the like. The addition of the diisocyan¬ ate reactant can be performed in one step (as in a two-step synthesis) or in multiple steps, usually two steps (as in a three-step synthesis) . The resultant mixture is then heated to a temperature below 100°C, preferably between about 80 and about 90°C for a period of time usually between about 7 hours and about 10 hours. The resultant mixture then is allowed to cool, usually to about room temperature and the diamine or short diol can be added to the mixture in order to effect the desired polymeric extension. Representative suitable diamines and diols include ethylene diamine, hydra- zine, ethylene glycol, butane-l,4-diol. All that is neces¬ sary is that the diamine or diol be capable of reacting with residual isocyanate groups. The preferred extender is ethyl- ene diamine. Given the amount of diisocyanate known, the amount of extender is calculated as to have a 2:1 mole ratio in a two-step synthesis, or a 3:1 ratio in a three-step synthesis. The extension reaction can be conducted at room temperature wherein the extender is usually added dropwise in solution of a suitable solvent such as 3% solution in di¬ methyl sulfoxide. The resultant product then is recovered by removing the solvent. The resultant product is rubbery and soluble in hexafluoroisopropanol, formic acid and m- cresol, but insoluble in N,N-dimethylformamide (DMF) . Thus,
SUBSiITϋis.. **r— - T REA7J
OMH these physical characteristics distinguish the products of this invention from other segmented polyurethanes which dis¬ solve in DMF and do not dissolve in hexafluoroisopropanol. The materials of this invention are extremely bland toward blood platelets and are therefore useful as coating on articles which are used in the body such as intravenous catheters, heart valves or the like. The compositions of this invention when cast as films from solutions, as examined by x-ray photoelectron spectroscopy, are nearly pure poiy- ether, generally about 80% or more which provides a strong basis that phase separation of the "hard segment" is much more complete and that the hard segment (diisocyanate-diamine) is below the surface. This contrasts with the prior art segmented polyurethanes which show no more than about 60% polyether at the surface.
Figures 1 and 2 are plotted as the number of elec¬ trons divided by their kinetic energy LN(E) as a function of their binding energy in electron volts when segmented polyurethanes are examined by x-ray photoelectron spectos- copy. Figure 1 shows the proportion of oxygen, nitrogen and carbon on the surface of a segmented polyurethane pre¬ pared from polyethylene oxide, molecular weight 15000, 2,4- tolylene diisocyanate, 4,4*-diphenylmethane diisocyanate and ethylene diamine by the three-step procedure generally set forth in Example I, but utilizing dimethylformamide as the solvent. This segmented polyurethane represents one of the best nonthrombogenic segmented polyurethanes made by the prior art process. It shows strong oxygen and carbon peaks and some nitrogen peaks. In contrast, the curve of Figure 2 which utilized the segmented polyurethane produced by the three-step procedure of Example I shows no nitrogen. A comparison of the carbon to oxygen ether bonds on each of these surfaces shows the prior art fraction of carbon bonded to ether to be only about 0.6 while that of the surface pro-
BSTITUTE SHEET O PI duced by the three-step procedure of Example I to be 0.82. If the surface were pure ethylene oxide, it would be 1.0.
The composition of this invention can be dissolved in a suitable solvent and the resultant composition can be coated on any device inserted or implanted in the body in order to reduce thrombogenicity of the device such as a heart valve, intravenous catheter or the like.
The following example illustrates the present inven¬ tion and is not intended to limit the same.
EXAMPLE I Two-Steps Procedure:
30 grams of poly(ethylene glycol) of molecular weight 1500 are added to 100 ml of a 1:1 mixture of dimethyl sul- foxide (DMSO) and 4-methyl-2-pentanone. 6.65 gr-ams of trans- 1,4-cyclohexane-diisocyanate are added into the mixture. The mixture is stirred under argon for 8 hours at 85 C. At this stage, the mixture becomes lemonly-yellow in colour and somewhat turbid. The reactor is allowed to cool to room temperature. 400 ml of DMSO are added to the cooled mixture. 1.22 grams of ethylenediamine is then added drop by drop to the reactor as a 3% solution in DMSO in continuous stirring. After an hour, the reaction is quenched with 100 ml of meth- anol. DMSO, methanol and 4-methyl-2-pentanone are evaporated to leave behind a lemonly-yellow gel-like polyurethane. The polyurethane is precipitated and extensively washed in dis¬ tilled water and dried in an oven at 60 C for a week, in vacuo. The product is rubbery and soluble in hexafluoroiso- propanol (HFIP) , formic acid, and m-cresol, but insoluble in N,N-dimethylformamide (DMF) .
Three-Steps Procedure:
30 grams of poly(ethylene glycol) of molecular weight 1500 are added to 100 ml of a 1:1 mixture of dimethyl sul-
OMPI . foxide (DMSO) and 4-methyl-2-pentanone. 1.66 grams of trans- 1,4-cyclohexane-diisocy.anate (CHDI) are then added into the mixture. The mixture is stirred under argon for 8 hours at 85°C. 3.32 grams of CHDI are added into the reactor and the mixture is stirred under argon for another 8 hours at 85 C. The mixture becomes lemonly-yellow and somewhat turbid. The reactor is allowed to cool to room temperature. 400 ml of DMSO are added to the cooled mixture. 0.61 grams of ethyl- enediamine is then added drop by drop to the reactor as a 3% solutionn DMSO in continuous stirring. After an hour, the reaction is quenched with 100 ml of methanol, DMSO, methanol and 4-methyl-2-pentanone are evaporated to leave behind a lemonly-yellow gel-like polyurethane. The poly¬ urethane is precipitated and extensively washed in distilled water and dried in an oven at 60 C for a week, in vacuo.
The product is rubbery and soluble in hexafluoroisopropanol (HFIP) , formic acid and m-cresol, but insoluble in N,N-di- methyl ormamide (DMF) .
O-IEA^

Claims

1. A segmented polyurethane comprising the reaction product of an α,ω diol polyalkylene oxide, 1,4-transcyclo- hexane diisocyanate and a polymer extender selected from the group consisting of a diamine, a short diol and mixtures thereof.
2. The composition of claim 1 wherein said poly¬ alkylene oxide is polyethylene oxide.
3. The composition of any one of claims 1 or 2 wherein said extender is a diamine.
4. The composition of any one of claims 1 or 2 wherein said extender is an ethylene diamine.
5. The composition of any one of claims 1 or 2 suspended in a solvent selected from the group consisting of hexafluoroisopropanol, formic acid and m-cresol.
6. The composition of claim 3 suspended in a solvent selected from the group consisting of hexafluoroisopropanol, formic acid and m-cresol.
7. The composition of claim 4 suspended in a solvent selected form the group consisting of hexafluoroisopropanol, formic acid and m-cresol.
8. An article suitable for implantation or insertion into the human body coated with the composition of claim 1.
9. An article suitable for implantation or insertion into the human body coated with the composition of claim 2. 10. An article suitable for implantation or insertion into the human body coated with the composition of claim 3.
11. An article suitable for implantation or insertion into the human body coated with the composition of claim 4.
EP19810902427 1981-08-26 1981-08-26 Segmented polyurethane composition. Withdrawn EP0086192A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1981/001156 WO1983000695A1 (en) 1981-08-26 1981-08-26 Segmented polyurethane composition

Publications (2)

Publication Number Publication Date
EP0086192A1 EP0086192A1 (en) 1983-08-24
EP0086192A4 true EP0086192A4 (en) 1983-12-01

Family

ID=22161399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19810902427 Withdrawn EP0086192A4 (en) 1981-08-26 1981-08-26 Segmented polyurethane composition.

Country Status (3)

Country Link
EP (1) EP0086192A4 (en)
JP (1) JPS58502211A (en)
WO (1) WO1983000695A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3318730A1 (en) * 1983-05-21 1984-11-22 Akzo Gmbh, 5600 Wuppertal Biocompatible polyurethanes
US5169720A (en) * 1986-11-18 1992-12-08 W. R. Grace & Co.-Conn. Protein non-adsorptive polyurea-urethane polymer coated devices
EP0335308B1 (en) * 1988-03-31 1993-12-08 W.R. Grace & Co.-Conn. Protein non-adsorptive polyurea-urethane polymer coated devices
US4892920A (en) * 1988-11-21 1990-01-09 Air Products And Chemicals, Inc. Process for the preparation of cyclohexanediisocyanate containing polyisocyanate prepolymers and polyurethanes having high temperature performance
JPH02234765A (en) * 1989-03-08 1990-09-17 Toray Ind Inc Antithrombus heart rate measuring catheter
GB8918589D0 (en) * 1989-08-15 1989-09-27 Graham Neil B Polymeric compositions
CA2274906A1 (en) * 1996-12-13 1998-06-18 Gregory J. Delmain Biocompatible medical devices with polyurethane surface

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2024233A (en) * 1978-07-03 1980-01-09 Akzo Nv Polyurethanes of trans - cyclohexane - 1,4 diisocyanate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5420560B2 (en) * 1971-11-20 1979-07-24
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3804812A (en) * 1972-11-03 1974-04-16 American Cyanamid Co Process for preparing a segmented linear polyurethane polymer
US4235988A (en) * 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2024233A (en) * 1978-07-03 1980-01-09 Akzo Nv Polyurethanes of trans - cyclohexane - 1,4 diisocyanate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8300695A1 *

Also Published As

Publication number Publication date
JPS58502211A (en) 1983-12-22
WO1983000695A1 (en) 1983-03-03
EP0086192A1 (en) 1983-08-24

Similar Documents

Publication Publication Date Title
EP1482997B1 (en) AnB BLOCK COPOLYMERS CONTAINING POLY(VINYL PYRROLIDONE) UNITS, MEDICAL DEVICES, AND METHODS
EP0396431B1 (en) Elastomeric segmented hydrophilic polyetherurethane based lubricious coatings
CA1335317C (en) Fluorinated polyetherurethanes and medical devices therefrom
AU711425B2 (en) Fluoroligomer surface modifiers for polymers and articles made therefrom
Park et al. PDMS-based polyurethanes with MPEG grafts: synthesis, characterization and platelet adhesion study
US4623347A (en) Antithrombogenic elastomer products
Takahara et al. Effect of surface hydrophilicity on ex vivo blood compatibility of segmented polyurethanes
US5059269A (en) Method of making an article having a hemocompatible surface
US4935480A (en) Fluorinated polyetherurethanes and medical devices therefrom
US4939007A (en) Article having a hemocompatible surface
JPS58132017A (en) Extrudable polyurethane for prosthesis
CN115300672A (en) Vascular graft with modified surface
EP0086192A4 (en) Segmented polyurethane composition.
AU686689B2 (en) Hydrophilic polyurethane
US6915168B1 (en) Medical devices containing segmented polyurethane biomaterials
JPH0249022A (en) Polyurethane polymer composition and production thereof
EP0205815A1 (en) Use of an antithrombogenic synthetic elastomer and process of preparation thereof
Rehman Biodegradable polyurethanes: biodegradable low adherence films for the prevention of adhesions after surgery
GB2202855A (en) Hydrophilic polyurethane composition
EP0988068B1 (en) Medical devices containing segmented polyurethane biomaterials
Chen et al. Synthesis, characterization, and platelet adhesion studies of novel aliphatic polyurethaneurea anionomers based on polydimethylsiloxane-polytetramethylene oxide soft segments
KR100285238B1 (en) Medical Polyurethane with Polydimethylsiloxane (PDMS) and Polyethylene Glycol (PEG)
JPH0748431A (en) Polyurethaneurea polymer for medical use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

17P Request for examination filed

Effective date: 19830902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19850625

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MERRILL, EDWARD W.

Inventor name: WAN, STEPHEN S.